Increased investment and rapid development of AI/ML tools for hit identification, multiparameter optimization, and in vivo property prediction are currently accelerating drug discovery in small molecules. Simultaneously, a rapid advancement in the field of de novo design in large molecule therapeutics is occurring. Despite these advances, delivering broad pipeline impact across a diverse target space continues to be a challenge. This panel will discuss opportunities and challenges, and approaches to unlock the potential burgeoning potential of AI/ML in drug discovery.